Loading...

Thermo Fisher Scientific Inc.

TN8.DEXETRA
Healthcare
Medical - Diagnostics & Research
371.35
-1.35(-0.36%)

Thermo Fisher Scientific Inc. (TN8.DE) Stock Overview

Explore Thermo Fisher Scientific Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

F

Score: N/A

Key Financials

Market Cap140.2B
P/E Ratio25.18
EPS (TTM)$14.57
ROE0.13%
Fundamental Analysis

AI Price Forecasts

1 Week$345.04
1 Month$318.52
3 Months$395.76
1 Year Target$514.04

TN8.DE Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Thermo Fisher Scientific Inc. (TN8.DE) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of F, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 57.50, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $514.04.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 25.18 and a market capitalization of 140.2B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

57.50RSI (14)
3.18MACD
13.79ADX
Revenue Growth
0.05%
0.05%
Profit Growth
17.24
5.67%
EPS Growth
17.24
6.76%
Operating Margin
17.08%
6.97%
ROE
13.34%
5.67%
Dividend Yield
0.00%
12.64%
Analyst Recommendations data is not available for TN8.DEAnalyst Recommendations details for TN8.DE are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the United States and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, clinical next-generation sequencing, bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, laboratory chemicals, research and safety market channel, and pharma services and clinical research. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

CEO

Marc N. Casper

Employees

125,000

Headquarters

168 Third Avenue, Waltham, MA

Founded

2020

Frequently Asked Questions

;